Antimitochondrial Antibody and AMA M2
Note: this site is for informational purposes only. To view test results or book a test, use the NHS app in England or contact your GP.
The AMA (anti-mitochondrial antibody) test is a blood test in which a sample is drawn from a vein to detect antibodies directed against mitochondrial antigens. It is used to help diagnose primary biliary cholangitis, an autoimmune liver condition.
Why get tested?
To help diagnose primary biliary cholangitis (PBC)
When to get tested?
When a doctor suspects that a person may have primary biliary cholangitis
Sample required?
A blood sample taken from a vein in your arm
Test preparation needed?
No test preparation is needed
What is being tested?
This test measures whether antimitochondrial antibodies (AMA) are present in the blood. Moderate or high levels of AMA are strongly associated with primary biliary cholangitis (PBC). PBC is an autoimmune disorder that causes inflammation and scarring of the bile ducts inside the liver, causing continual liver damage and blockage of the bile flow. It is found most frequently in women between the ages of 35 and 60. More than 90% of those affected by PBC will have high levels of antimitochondrial antibodies.
Increased AMA levels are seen much less often in autoimmune hepatitis, primary sclerosing cholangitis, liver disease due to chronic inflammatory bowel disease, and bile duct obstruction.
There are nine types of AMA (M1 – M9) of which M2 is the most clinically valuable. M2 antibodies target the pyruvate dehydrogenase complex (PDC). The presence of the M2 type has been particularly evident in primary biliary cholangitis, while the other AMA types may be found in other conditions.
In some laboratories, if testing for AMA is positive, then further tests for the M2 subtype is performed. Some laboratories have started to offer the AMA-M2 test instead of the AMA, which reduces the number of false positives from non-M2 antibodies.
Some laboratories use a test that looks at the fused subunits of the M2 antigen (BPO or M2-3E) and the implications of that being positive or negative are the same as the M2-PDC test.
Approximately 10% of patients with PBC will not have M2 antibodies. Other ANA related antibodies may also be tested in this setting. These are PML (Promyelocytic Leukemia antigen), SP100 (nuclear body protein sp100 ) and GP210 (nuclear pore membrane protein gp210 )these are also highly specific for PBC. The PML antigen is found in healthy cells and antibodies to it do not imply the patient has leukaemia.
Common questions
The AMA test is requested to help diagnose primary biliary cholangitis (PBC). PBC is a serious condition in which the bile system in the liver is gradually destroyed.
Other tests that may be requested include:
- Smooth muscle antibodies (SMA)
- Antinuclear antibodies (ANA)
- Ro52 Antibody
- Antibodies to M2-3E, SP100, GP210, PML
- Levels of immunoglobulins (IgM, IgG, IgA)
- Liver function tests ( Bilirubin, Alkaline phosphatase, GGT, Alanine transaminase, Aspartate transaminase, Albumin)
- Prothrombin time
- C‑reactive protein
- Abdominal ultrasound
- Magnetic resonance cholangiopancreatography (MRCP)
- Liver biopsy
These tests can help in the diagnosis of PBC, and may distinguish it from other autoimmune conditions which can cause liver damage, and they may provide information about the degree of liver damage.
The AMA or AMA-M2/M2-3E test is requested when your doctor suspects that you have an autoimmune disorder such as PBC. You may have symptoms such as tiredness (fatigue), jaundice and itchiness, but many patients affected with early PBC have no symptoms. The condition is often initially identified because a patient has elevated levels of enzymes which come from the liver and indicated that it is diseased. The enzyme alkaline phosphatase (ALP), is often elevated and this is found during routine blood tests.
An AMA or AMA-M2/M2-3E test may be requested with or following a variety of tests that are used to help diagnose and/or rule out other causes of liver disease or injury. These causes can include infections, such as viral hepatitis, drugs, alcohol abuse, toxins, genetic conditions, metabolic conditions, and autoimmune hepatitis.
High levels of AMA or AMA-M2/M2-3E in the blood are most likely due to PBC. Low levels of AMA may also be present in patients with autoimmune hepatitis, liver or bile obstruction, and with infections such as syphilis or acute infectious hepatitis. AMA may also be present in patients with other autoimmune disorders related to PBC such as systemic lupus erythematosus, Sjogren syndrome, Coeliac disease and thyroiditis.
Levels of AMA may be lower in children and in those with compromised immune systems. The level of AMA is not related to the severity of PBC symptoms or to a patient’s prognosis. Patients who have symptoms or laboratory findings suggestive of PBC but with a negative AMA will usually be tested for other related antibodies e.g. PML. SP100, GP210.
By themselves, AMA and AMA-M2/M2-3E can not be used to diagnose PBC, but in conjunction with other laboratory tests and clinical symptoms, a diagnosis of PBC can be made. When high levels of AMA or AMA-M2/M2-3E are present and the doctor suspects PBC, a liver biopsy may be performed to look for the signs of primary biliary cholangitis in the liver tissue. Imaging scans of the liver may also be used to look for bile duct obstruction.
About 50% of the cases of PBC will be discovered before the patient has noticeable symptoms.
The cause of PBC is currently not known. It appears to be an autoimmune condition. It is not infectious and not inherited. It can occur in anyone at any age, but it is primarily seen in middle-aged women.
The course and severity of PBC is difficult to predict. Many patients will have no or few symptoms for many years. For more information, consult with your doctor and see the Related content below.
Up to 0.5% of the population are M2 AMA positive, only 10% of these will ever go on to develop PBC. PBC can only be diagnosed with the combination of abnormal liver function tests (e.g. raised alkaline phosphatase) and autoantibodies e.g. M2 AMA (with or without a liver biopsy).
If liver function is normal at baseline it could be repeated annually if the M2 antibody is confirmed on a second (repeat) test, with the reassurance that 90% of people will never develop problems.